Le Tourneau, Christophe http://orcid.org/0000-0001-9772-4686
Delord, Jean-Pierre
Kotecki, Nuria
Borcoman, Edith
Gomez-Roca, Carlos
Hescot, Ségolène
Jungels, Christiane
Vincent-Salomon, Anne
Cockenpot, Vincent
Eberst, Lauriane
Molé, Audrey
Jdey, Wael
Bono, Françoise
Trochon-Joseph, Véronique
Toussaint, Hélène
Zandanel, Christelle
Adamiec, Olga
de Beaumont, Olivier
Cassier, Philippe Alexandre http://orcid.org/0000-0003-3857-1688
Article History
Received: 12 May 2020
Revised: 15 July 2020
Accepted: 30 July 2020
First Online: 25 August 2020
Ethics approval and consent to participate
: The study received approval from the Central Ethics Committees of “Rennes Ouest V” in France and Central Ethics Committee of “Institut Jules Bordet”, Brussels in Belgium. The study was performed in accordance with the Declaration of Helsinki. A written informed consent was obtained from each patient prior to study enrolment.
: Anonymised data set may be available from the corresponding author on request.
: C.L.T. participated in advisory boards from MSD, BMS, Merck Serono, GSK, Astra Zeneca, Nanobiotix, Roche, Rakuten, Seatlle Genetics and Celgene. C.G.R. received grant from BMS, consulting fees from Roche, BMS, Pierre Fabre and Erytech and support for travel from Roche, BMS, Pierre Fabre and MSD. P.A.C. received honoraria from Astra Zeneca, Amgen, EMD-serono, Novartis and Roche. J.-P.D., N.K., E.B., S.H., C.J., A.V.-S., V.C. and L.E. declared no conflict of interest. A.M., W.J., F.B., O.A., O.d.B., V.T.-J. and C.Z. are employees of Onxeo and have declared to have stock options from the company (Onxeo). H.T. was an employee of Onxeo. She has declared no conflict of interest.
: The trial was sponsored by Onxeo SAS, France. Costs for technical support, article processing and Open Access were funded by Onxeo SAS.